Posted by ABMN Staff on Nov 8th, 2018 // No Comments
Sanofi (NYSE:SNY) had its price objective upped by stock analysts at Argus from $48.00 to $50.00 in a note issued to investors on Thursday. The firm presently has a “buy” rating on the stock. Argus’ price target suggests a potential upside of 11.11% from the stock’s current price.
Several other brokerages also recently weighed in on SNY. ValuEngine upgraded shares of Sanofi from a “strong sell” rating to a “sell” rating in a research note on Friday, July 20th. Guggenheim initiated coverage on shares of Sanofi in a research report on Monday, October 8th. They issued a “neutral” rating for the company. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a research report on Monday, October 15th. TheStreet upgraded shares of Sanofi from a “c+” rating to a “b” rating in a research report on Thursday, July 12th. Finally, Wolfe Research initiated coverage on shares of Sanofi in a research report on Tuesday, October 23rd. They issued a “market perform” rating for the company. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $49.50. Get Sanofi alerts:
Shares of SNY traded down $0.33 during mid-day trading on Thursday, hitting $45.00. 913,411 shares of the company’s stock were exchanged, compared to its average volume of 1,610,060. Sanofi has a fifty-two week low of $37.43 and a fifty-two week high of $46.25. The company has a market capitalization of $111.91 billion, a price-to-earnings ratio of 14.38, a price-to-earnings-growth ratio of 2.53 and a beta of 0.70. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.85 and a current ratio of 1.22.
Sanofi (NYSE:SNY) last announced its earnings results on Wednesday, October 31st. The company reported $1.07 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.09. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The business had revenue of $9.39 billion during the quarter, compared to the consensus estimate of $9.10 billion. During the same quarter in the prior year, the firm earned $1.71 earnings per share. The business’s quarterly revenue was up 1.5% compared to the same quarter last year. Equities research analysts forecast that Sanofi will post 3.09 EPS for the current year.
In related news, major shareholder Sanofi sold 104,552 shares of the firm’s stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $406.68, for a total value of $42,519,207.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink . 1.00% of the stock is owned by company insiders.
Several hedge funds have recently bought and sold shares of the company. Huntington National Bank lifted its position in shares of Sanofi by 24.9% during the 2nd quarter. Huntington National Bank now owns 6,037 shares of the company’s stock valued at $242,000 after acquiring an additional 1,202 shares during the period. Advisor Partners LLC lifted its position in shares of Sanofi by 23.7% during the 2nd quarter. Advisor Partners LLC now owns 6,503 shares of the company’s stock valued at $260,000 after acquiring an additional 1,245 shares during the period. Wealthstreet Investment Advisors LLC lifted its position in shares of Sanofi by 14.3% during the 3rd quarter. Wealthstreet Investment Advisors LLC now owns 10,392 shares of the company’s stock valued at $464,000 after acquiring an additional 1,300 shares during the period. Pekin Singer Strauss Asset Management IL lifted its position in shares of Sanofi by 3.6% during the 2nd quarter. Pekin Singer Strauss Asset Management IL now owns 38,355 shares of the company’s stock valued at $1,535,000 after acquiring an additional 1,315 shares during the period. Finally, Steward Partners Investment Advisory LLC lifted its position in shares of Sanofi by 8.3% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 18,344 shares of the company’s stock valued at $734,000 after acquiring an additional 1,401 shares during the period. Institutional investors own 7.53% of the company’s stock.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis. Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter . «
